Vistagen Therapeutics Inc (VTGN) Stock Price, Quote & News

Company Profile

Vistagen Therapeutics, Inc., a clinical-stage biopharmaceutical company, engages in the development and commercialization of therapies for neuropsychiatric and neurological disorders. The company's product pipeline includes Fasedienol, an investigational pherine nasal spray that is in Phase III clinical trial for the treatment of anxiety in adults with social anxiety disorder; and Itruvone, an odorless synthetic investigational neuroactive pherine nasal spray, which is in Phase II clinical trial...

Industry: Biotechnology

Sector: Healthcare

Phone: 650 577 3600

Website: www.vistagen.com

Address:

343 Allerton Avenue, South San Francisco, United States

BioBum May. 15 at 9:31 PM

$VTGN TCG Crossover GP now owns 2.6%. Sounds like a gamertag on Xbox

0 · Reply

DAP89 May. 15 at 9:31 PM

$VTGN https://www.sec.gov/Archives/edgar/data/1411685/000119312526226886/xslSCHEDULE_13G_X02/primary_doc.xml

0 · Reply

DAP89 May. 15 at 9:27 PM

$VTGN hope you all are paying attention!!! 13fs 13 gs out

1 · Reply

TornadoChasers May. 15 at 4:41 PM

$VTGN $OCGN $PSKY $GNS Merger

2 · Reply

SnoopDawg May. 15 at 9:05 AM

$VTGN my options expire today. No need to roll them the shares are cheaper.

0 · Reply

ewuzi01 May. 15 at 1:02 AM

$VTGN

0 · Reply

AStrokeOfLuck May. 14 at 3:08 PM

$VTGN

0 · Reply

jcooptechit May. 14 at 2:42 PM

$CELZ COULD BE ONE CATALYST AWAY FROM A MAJOR MOMENTUM RE-RATE Creative Medical is tightening right as CELZ-201-DDT Phase 2 results for chronic low-back pain are expected in May 2026. Key levels on watch: * Accumulation: $1.70–$1.82 * Reaccumulation: $2.02–$2.20 * Breakout: $2.32 * Major Resistance: $2.72 🎯 Target Zone: $3.31–$3.68 The roadmap is simple: hold $2.02–$2.20, reclaim $2.32, attack $2.72, then eyes on $3.31+ With Phase 2 results potentially due any day now, volume confirmation could turn this setup from quiet accumulation into a serious catalyst-driven move. Keep CELZ locked in. Communicated - Disclaimer: https://fh.bio/jcoop Sector Peers: $VTGN $LCTX $ATHX.X $PSTV

0 · Reply

Bulltrader988 May. 14 at 12:38 PM

$VTGN "..., will participate in a fireside chat at the RBC Capital Markets Global Healthcare conference on Wednesday, May 20, 2026, at 2:35 p.m. Eastern Time. The Company will also host one-on-one meetings during the conference..." 👃👀 https://www.stocktitan.net/news/VTGN/vistagen-to-participate-in-the-2026-rbc-capital-markets-global-f5wlbholbnup.html

0 · Reply

marketCaptain May. 14 at 9:47 AM

$VTGN yellow, red or green?

2 · Reply

Vistagen to Participate in the 2026 RBC Capital Markets Global Healthcare Conference

2026-05-12T11:52:14.000Z - 3 days ago

Vistagen reports preliminary positive data on ongoing PALISADE-3 study

May 12, 2026, 7:30 AM EDT - 3 days ago

Vistagen Announces Preliminary Positive Data in Ongoing Open-Label Extension Portion of PALISADE-3 Phase 3 Study of Fasedienol for the Acute Treatment of Social Anxiety Disorder

2026-05-08T12:22:06.000Z - 7 days ago

Vistagen announces completion of last patient visit in PALISADE-4 study

May 8, 2026, 7:30 AM EDT - 7 days ago

Vistagen Announces Completion of Last Patient Visit in PALISADE-4 Phase 3 Public Speaking Challenge Study of Fasedienol for Acute Treatment of Social Anxiety Disorder

2026-04-22T14:45:36.000Z - 23 days ago

AbCellera target is profile more attractive than Vistagen, says JonesResearch

ABCL

2026-04-22T13:41:58.000Z - 23 days ago

Vistagen receives FDA ‘Study May Proceed’ letter under refisolone IND filing

Apr 22, 2026, 8:30 AM EDT - 23 days ago

Vistagen Receives FDA “Study May Proceed” Letter Under its Refisolone IND Application, Enabling Further Phase 2 Clinical Development for the Treatment of Vasomotor Symptoms (Hot Flashes) due to Menopause

Mar 17, 2026, 9:00 AM EDT - 2 months ago

Vistagen Therapeutics Transcript: Stifel 2026 Virtual CNS Forum

Mar 3, 2026, 8:30 AM EST - 2 months ago

Vistagen to Participate in Upcoming Investor Conferences

Mar 2, 2026, 3:50 PM EST - 2 months ago

Vistagen Therapeutics Transcript: TD Cowen 46th Annual Health Care Conference

2026-02-25T17:53:19.000Z - 2 months ago

Vistagen Facing Class Action over Social Anxiety Disorder Drug Claims

Feb 25, 2026, 8:30 AM EST - 2 months ago

Vistagen to Participate in the 46th Annual TD Cowen Healthcare Conference

Feb 12, 2026, 5:00 PM EST - 3 months ago

Vistagen Therapeutics Earnings Call Transcript: Q3 2026

Feb 12, 2026, 4:30 PM EST - 3 months ago

Vistagen Reports Fiscal Year 2026 Third Quarter Financial Results and Provides Corporate Update

Feb 6, 2026, 9:52 AM EST - 3 months ago

VTGN Investors Encouraged to Seek Lead Plaintiff Role in Vistagen Therapeutics Securities Class Actoin Case with Johnson Fistel

Feb 4, 2026, 8:30 AM EST - 3 months ago

Vistagen to Report Fiscal Year 2026 Third Quarter Results and Host Corporate Update Conference Call on February 12, 2026

Jan 22, 2026, 10:45 AM EST - 4 months ago

VISTAGEN THERAPEUTICS, INC. (NASDAQ: VTGN) DEADLINE ALERT – Bernstein Liebhard LLP Reminds Vistagen Therapeutics, Inc. Investors of Upcoming Deadline

Jan 16, 2026, 5:06 PM EST - 4 months ago

VISTAGEN THERAPEUTICS, INC. (NASDAQ: VTGN) INVESTOR ALERT Investors With Large Losses in Vistagen Therapeutics, Inc. Should Contact Bernstein Liebhard LLP To Discuss Their Rights

2025-12-17T19:25:24.000Z - 5 months ago

Vistagen downgraded to Hold from Buy at Jefferies

2025-12-17T19:25:11.000Z - 5 months ago

Vistagen downgraded to Hold at Jefferies after social anxiety study miss

2025-12-17T17:20:14.000Z - 5 months ago

Vistagen downgraded to Hold from Buy at Maxim

2025-12-17T16:35:29.000Z - 5 months ago

Vistagen downgraded to Market Perform from Outperform at William Blair

2025-12-17T16:35:21.000Z - 5 months ago

Vistagen downgraded to Market Perform at William Blair after PALISADE-3 miss

2025-12-17T15:50:39.000Z - 5 months ago

Vistagen downgraded to Hold at Stifel after PALISADE-3 study disappoints

2025-12-17T15:45:17.000Z - 5 months ago

Vistagen downgraded to Hold from Buy at Stifel

2025-12-17T14:40:46.000Z - 5 months ago

Vistagen downgraded to Neutral from Buy at Lucid Capital

2025-12-17T14:05:58.000Z - 5 months ago

Vistagen SAD study did not achieve primary endpoint

2025-12-17T13:55:10.000Z - 5 months ago

VistaGen Therapeutics trading resumes

Dec 17, 2025, 8:30 AM EST - 5 months ago

Vistagen Announces Topline Results from PALISADE-3 Phase 3 Public Speaking Challenge Study of Fasedienol for the Acute Treatment of Social Anxiety Disorder

2025-12-17T13:25:17.000Z - 5 months ago

VistaGen Therapeutics trading halted, news pending

2025-12-01T14:00:20.000Z - 5 months ago

Vistagen names Nick Tressler CFO

Dec 1, 2025, 8:30 AM EST - 5 months ago

Vistagen Appoints Nick Tressler as Chief Financial Officer

2025-11-26T13:40:25.000Z - 6 months ago

Vistagen presents exploratory PH80 data at Menopause Society meeting

Nov 26, 2025, 8:30 AM EST - 6 months ago

Vistagen Reports Findings on PH80's Brain and Autonomic Effects in Women with Menopausal Hot Flashes at The Menopause Society 2025 Annual Meeting

Nov 13, 2025, 5:00 PM EST - 6 months ago

Vistagen Therapeutics Earnings Call Transcript: Q2 2026

Nov 13, 2025, 4:30 PM EST - 6 months ago

Vistagen Reports Fiscal Year 2026 Second Quarter Financial Results and Provides Corporate Update

Nov 12, 2025, 3:20 PM EST - 6 months ago

Vistagen Therapeutics Transcript: Stifel 2025 Healthcare Conference

Nov 10, 2025, 8:30 AM EST - 6 months ago

Vistagen to Report Fiscal Year 2026 Second Quarter Results and Host Corporate Update Conference Call on November 13, 2025

Nov 5, 2025, 8:30 AM EST - 6 months ago

Vistagen to Participate in Stifel Healthcare Conference 2025

Nov 3, 2025, 8:30 AM EST - 6 months ago

Vistagen Completes PALISADE-3 Phase 3 Public Speaking Challenge Study for the Acute Treatment of Social Anxiety Disorder

Oct 29, 2025, 8:30 AM EDT - 7 months ago

Vistagen Appoints Paul Edick to its Board of Directors

Oct 16, 2025, 8:30 AM EDT - 7 months ago

Vistagen to Present at The Menopause Society 2025 Annual Meeting

Sep 18, 2025, 2:20 PM EDT - 8 months ago

Vistagen Therapeutics Transcript: TD Cowen's 5th Annual Novel Mechanisms in Neuropsychiatry & Epilepsy Summit

Sep 9, 2025, 12:00 PM EDT - 8 months ago

Vistagen Therapeutics Transcript: AGM 2025

Sep 9, 2025, 8:30 AM EDT - 8 months ago

Vistagen to Present at the TD Cowen 5th Annual Novel Mechanisms in Neuropsychiatry & Epilepsy Summit

Aug 7, 2025, 5:00 PM EDT - 10 months ago

Vistagen Therapeutics Earnings Call Transcript: Q1 2026

Aug 7, 2025, 4:30 PM EDT - 10 months ago

Vistagen Reports Fiscal Year 2026 First Quarter Financial Results and Corporate Update

Jul 31, 2025, 8:30 AM EDT - 10 months ago

Vistagen to Report Fiscal Year 2026 First Quarter Results and Host Corporate Update Conference Call on August 7, 2025

Jul 24, 2025, 8:30 AM EDT - 10 months ago

Vistagen to Present at the BTIG Virtual Biotechnology Conference

Jul 15, 2025, 8:30 AM EDT - 10 months ago

Vistagen Honored for Outstanding Workplace Culture and Mental Health Leadership

Jun 25, 2025, 8:30 AM EDT - 11 months ago

Vistagen Appoints Elissa Cote as Chief Corporate Development Officer

Jun 17, 2025, 5:00 PM EDT - 11 months ago

Vistagen Therapeutics Earnings Call Transcript: Q4 2025

Jun 17, 2025, 4:30 PM EDT - 11 months ago

Vistagen Reports Fiscal Year 2025 Financial Results and Provides Corporate Update

Jun 12, 2025, 8:30 AM EDT - 1 year ago

Vistagen to Report Fiscal Year 2025 Financial Results and Host Corporate Update Conference Call on June 17, 2025

Jun 5, 2025, 11:40 AM EDT - 1 year ago

Vistagen Therapeutics Transcript: Jefferies Global Healthcare Conference 2025

Jun 2, 2025, 8:30 AM EDT - 1 year ago

Vistagen on Track to Deliver Topline Data From Fasedienol PALISADE-3 Phase 3 Trial for Acute Treatment of Social Anxiety Disorder in the Fourth Quarter of This Year

May 28, 2025, 8:30 AM EDT - 1 year ago

Vistagen to Present at the Jefferies 2025 Global Life Sciences Conference New York

May 23, 2025, 8:30 AM EDT - 1 year ago

Vistagen to Present at the 2025 American Society of Clinical Psychopharmacology Conference

Apr 17, 2025, 8:30 AM EDT - 1 year ago

Vistagen Presents New Research on the Impact of Social Anxiety Disorder at The Anxiety and Depression Association 2025 Conference

Mar 19, 2025, 8:30 AM EDT - 1 year ago

Vistagen to Present at the 2025 Anxiety and Depression Association Conference

Mar 18, 2025, 12:00 PM EDT - 1 year ago

Vistagen Therapeutics Transcript: Stifel 2025 Virtual CNS Forum

Mar 4, 2025, 8:30 AM EST - 1 year ago

Vistagen to Participate in Stifel 2025 Virtual CNS Forum

Mar 3, 2025, 1:30 PM EST - 1 year ago

Vistagen Therapeutics Transcript: TD Cowen 45th Annual Health Care Conference

Feb 20, 2025, 8:30 AM EST - 1 year ago

Vistagen to Participate in the 45th Annual TD Cowen Healthcare Conference

Feb 13, 2025, 5:00 PM EST - 1 year ago

Vistagen Therapeutics Earnings Call Transcript: Q3 2025

Feb 13, 2025, 4:30 PM EST - 1 year ago

Vistagen Reports Fiscal Year 2025 Third Quarter Financial Results and Corporate Update

Feb 6, 2025, 8:30 AM EST - 1 year ago

Vistagen to Report Fiscal Year 2025 Third Quarter Results and Host Corporate Update Conference Call on February 13, 2025

Feb 5, 2025, 8:30 AM EST - 1 year ago

Vistagen Receives U.S. Patent for AV-101 to Treat Neuropathic Pain

BioBum May. 15 at 9:31 PM

$VTGN TCG Crossover GP now owns 2.6%. Sounds like a gamertag on Xbox

0 · Reply

DAP89 May. 15 at 9:31 PM

$VTGN https://www.sec.gov/Archives/edgar/data/1411685/000119312526226886/xslSCHEDULE_13G_X02/primary_doc.xml

0 · Reply

DAP89 May. 15 at 9:27 PM

$VTGN hope you all are paying attention!!! 13fs 13 gs out

1 · Reply

TornadoChasers May. 15 at 4:41 PM

$VTGN $OCGN $PSKY $GNS Merger

2 · Reply

SnoopDawg May. 15 at 9:05 AM

$VTGN my options expire today. No need to roll them the shares are cheaper.

0 · Reply

ewuzi01 May. 15 at 1:02 AM

$VTGN

0 · Reply

AStrokeOfLuck May. 14 at 3:08 PM

$VTGN

0 · Reply

jcooptechit May. 14 at 2:42 PM

0 · Reply

Bulltrader988 May. 14 at 12:38 PM

0 · Reply

marketCaptain May. 14 at 9:47 AM

$VTGN yellow, red or green?

2 · Reply

TheBearDestroyer May. 13 at 8:13 PM

$GNS $PSKY $VTGN Watch out for this cowboy and his band of merry men.

0 · Reply

marketCaptain May. 13 at 8:06 PM

$VTGN Price target if fasedienol gets to market?

1 · Reply

Bulltrader988 May. 13 at 6:46 PM

$VTGN High risk high reward 👃👀 https://x.com/i/status/2054194540160909800

1 · Reply

jeffthechef May. 13 at 5:54 PM

@ACInvestorBlog $VTGN 👍

0 · Reply

DAP89 May. 13 at 5:27 PM

$VTGN Acadian asset mgmt in with 590,000 shares

0 · Reply

Esterostktrader May. 13 at 4:18 PM

$VTGN another day, another 1k plus calls traded. Someone buying large numbers of calls each day

2 · Reply

Lyn30 May. 13 at 4:03 PM

$VTGN Anyday 💥

0 · Reply

jeffthechef May. 13 at 2:10 PM

@ACInvestorBlog $VTGN watching this closely. Had news yesterday!

0 · Reply

joe77w May. 13 at 10:32 AM

$VTGN 20/23 USD would equate to 1 bln usd, then followed by financing to crystallize value. This the best scenario otherwise stock would collapse below 40 cents. Just my opinion, this Is asymmetric bet, you gain stellar Money worth X the Money put in or you lose 1/3, 2/5 Capital. Do your dd before investing your Money, risk Is neverthless High, recent failed PALISADE 3 put a dark shadow on the entire program, maybe VISTAGEN to Surprise as for PALISADE 2 (stock went up 1400% to24 USD)

0 · Reply

joe77w May. 13 at 10:27 AM

$VTGN If PALISADE 4 data positive, whole PIPELINE based on PHERINE Will be re/evaluated, market cap could really exceed 1 BLN USD given the huge market potential. Current meager pps does only mean market does not have any trust in VISTAGEN, currently trading at liquidation value, at Fire sale prices.

0 · Reply

To_De_Moon May. 13 at 7:14 AM

$VTGN this will be over 10$ next month 🔥

2 · Reply

Hellodaniel May. 12 at 10:52 PM

$VTGN The fact that they submitted existing data to the SEC to formalize it implies that they have established solid grounds. However, the important thing is the results of P4; if the outcome is positive, I think there will be a massive explosion. This is a do-or-die situation.

1 · Reply

Market Cap	25.98M
Revenue (ttm)	490,000.00
Net Income (ttm)	-51.42M
EPS (ttm)	N/A
PE Ratio	0.00
Forward PE	N/A
Profit Margin	-10,493.88%
Debt to Equity Ratio	0.00

Volume	657,900
Avg Vol	795,440
Day's Range	N/A - N/A
Shares Out	39.62M
Stochastic %K	60%
Beta	0.31
Analysts	Hold
Price Target	$0.97